Navigation Links
Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
Date:8/4/2009

BRIDGEWATER, N.J., Aug. 4 /PRNewswire-FirstCall/ -- With acne being one of the most common skin diseases affecting nearly 80 percent of people between the ages of 12 and 24, Dermik Laboratories, a business of sanofi-aventis U.S., announced today the availability of the BenzaClin(R) (clindamycin 1%-benzoyl peroxide 5% gel) carekit, a unique prescribing option for patients with acne who want to add a moisturizing agent to their skin care regimen.

The BenzaClin carekit features the 50g BenzaClin(R) PUMP packaged with 20 ampoules of Viscontour(R) Serum, a cosmetic product. Viscontour Serum topical hyaluronic acid offers a simple and convenient way of moisturizing the skin. When applied topically Viscontour acts as a natural moisture reservoir for the skin.

"We are excited about the availability of the BenzaClin carekit because it broadens the landscape of what physicians can offer their patients who are seeking a moisturizing agent while using BenzaClin for their acne," says Brent Ragans, Vice President and Head of the General Therapeutics Business Unit, sanofi-aventis.

While maintaining moisture can be a challenge for teens and young adults dealing with acne, the arrival of the carekit offers an acne treatment and a moisturizer under one easy to write prescription.

In addition to the BenzaClin carekit, patients can choose from a variety of prescribing options including the one-of-a-kind BenzaClin 50g PUMP, which is the flagship of the BenzaClin line of products, as well as the BenzaClin(R) 25g jar.

BenzaClin is a topical, prescription acne treatment that combines the acne-fighting power of benzoyl peroxide and clindamycin, and has been shown to reduce acne in as little as two weeks. For more information about the BenzaClin carekit and the BenzaClin prescribing family, visit www.BenzaClin.com or for more information about acne please visit www.AcneHeroes.com .

About BenzaClin(R)

BenzaClin(R) is proven effective in treating acne, including whiteheads, blackheads, and pimples. In clinical trials, BenzaClin(R) worked better than either individual components, clindamycin or benzoyl peroxide alone for the topical treatment of acne. With BenzaClin(R), improvements have been shown to occur in as early as two weeks.

BenzaClin(R) is indicated for the topical treatment of acne.

Important Safety Information

BenzaClin(R) was studied in mild to moderate acne patients. BenzaClin(R) is an acne product you can get with a doctor's prescription. Side effects are usually limited to the skin and include dry skin, itching, peeling, redness and sunburn. Also, clindamycin, an ingredient in BenzaClin(R), may cause diarrhea. If you experience severe diarrhea, stop using BenzaClin(R) and call your doctor immediately. You should not use BenzaClin(R) if you are allergic to clindamycin, benzoyl peroxide, or the antibiotic lincomycin, or if you have a history of colitis.

Please see full prescribing information at www.benzaclin.com.

About Viscontour(R)

Viscontour(R) Serum is a cosmetic hydration agent that offers you a simple and convenient way of moisturizing your skin. Applied topically, Viscontour(R) Serum works to help restore and sustain hydration.

About sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, www.sanofi-aventis.us or www.sanofi-aventis.com

    Contacts
    Amy Ba
    Tel: 908-981-6563
    Mobile: 646-207-4935
    Email: amy.ba@sanofi-aventis.com


'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Sanofi-aventis Announces Second Quarter 2009 Results
11. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 Research and Markets has ... report to their offering. ... The Global Market for Bioproducts ... 2016 at a CAGR of 8.9%, This ... bioproducts into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
Breaking Biology News(10 mins):